• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌转移的分子生物学。运用数学模型来确定乳腺癌的复发情况并预测其对化疗的反应。

Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer.

作者信息

Clare S E, Nakhlis F, Panetta J C

机构信息

Department of Surgery, Northwestern University Medical School, Northwestern Memorial Hospital, Chicago, Illinois 60611-3010, USA.

出版信息

Breast Cancer Res. 2000;2(6):430-5. doi: 10.1186/bcr90. Epub 2000 Jul 21.

DOI:10.1186/bcr90
PMID:11250737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC138666/
Abstract

Breast cancer mortality rates have shown only modest improvement despite the advent of effective chemotherapeutic agents which have been administered to a large percentage of women with breast cancer. In an effort to improve breast cancer treatment strategies, a variety of mathematical models have been developed that describe the natural history of breast cancer and the effects of treatment on the cancer. These models help researchers to develop, quantify, and test various treatment hypotheses quickly and efficiently. The present review discusses several of these models, with a focus on how they have been used to predict the initiation time of metastatic growth, the effect of operative therapy on the growth of metastases, and the optimal administration strategy for chemotherapy.

摘要

尽管已经有有效的化疗药物可供大部分乳腺癌女性使用,但乳腺癌死亡率仅略有改善。为了改进乳腺癌治疗策略,人们开发了多种数学模型,这些模型描述了乳腺癌的自然病史以及治疗对癌症的影响。这些模型有助于研究人员快速有效地开发、量化和测试各种治疗假设。本综述讨论了其中的几种模型,重点关注它们如何用于预测转移生长的起始时间、手术治疗对转移灶生长的影响以及化疗的最佳给药策略。

相似文献

1
Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer.乳腺癌转移的分子生物学。运用数学模型来确定乳腺癌的复发情况并预测其对化疗的反应。
Breast Cancer Res. 2000;2(6):430-5. doi: 10.1186/bcr90. Epub 2000 Jul 21.
2
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.开发晚期或早期自发转移临床前模型以研究抗血管生成药物、节拍化疗和肿瘤微环境的十年经验。
Cancer J. 2015 Jul-Aug;21(4):274-83. doi: 10.1097/PPO.0000000000000134.
3
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.采用环磷酰胺、甲氨蝶呤和氟尿嘧啶辅助化疗治疗的20多年来淋巴结阳性原发性乳腺癌的自然病史:癌症与白血病B组的一项研究
J Clin Oncol. 2003 May 1;21(9):1825-35. doi: 10.1200/JCO.2003.09.006.
4
Ten-year outcome after combined modality therapy for inflammatory breast cancer.炎性乳腺癌综合治疗后的十年预后
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1200-8. doi: 10.1016/s0360-3016(02)04201-3.
5
Randomized clinical trials in breast cancer: a tabular summary. Part 1: Primary breast cancer.乳腺癌随机临床试验:表格总结。第1部分:原发性乳腺癌。
Arch Geschwulstforsch. 1986;56(3):211-36.
6
[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies].[乳腺癌辅助治疗的最佳持续时间:何种证据?化疗:临床研究实例]
Suppl Tumori. 2004 Jul-Aug;3(4):S77-8.
7
Metronomic chemotherapy for advanced breast cancer patients.节拍化疗用于晚期乳腺癌患者。
Cancer Lett. 2017 Aug 1;400:252-258. doi: 10.1016/j.canlet.2016.12.019. Epub 2016 Dec 23.
8
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.使用早期或晚期乳腺癌转移模型对抗血管生成药物临床疗效进行临床前再现。
Breast. 2013 Aug;22 Suppl 2:S57-65. doi: 10.1016/j.breast.2013.07.011.
9
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.
Breast Cancer Res Treat. 2001 Jan;65(1):71-5. doi: 10.1023/a:1006476401801.
10
[Surgery for advanced breast cancer from the viewpoint of medical oncologist].
Gan To Kagaku Ryoho. 2007 Jun;34(6):858-61.

引用本文的文献

1
Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study.液体活检和患者报告的结局测量在早期乳腺癌患者综合监测中的应用:前瞻性乳腺癌生物样本库(PBCB)纵向观察研究的研究方案。
BMJ Open. 2022 Apr 29;12(4):e054404. doi: 10.1136/bmjopen-2021-054404.
2
Estimating latent, dynamic processes of breast cancer tumour growth and distant metastatic spread from mammography screening data.从乳房X光筛查数据中估计乳腺癌肿瘤生长和远处转移扩散的潜在动态过程。
Stat Methods Med Res. 2022 May;31(5):862-881. doi: 10.1177/09622802211072496. Epub 2022 Feb 1.
3
A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer.一种预测雌激素受体/孕激素受体/人表皮生长因子受体2/ Ki-67亚型乳腺癌患者继发性远处转移诊断期的数学模型。
Cancers (Basel). 2020 Aug 19;12(9):2344. doi: 10.3390/cancers12092344.
4
Consolidated mathematical growth model of the primary tumor and secondary distant metastases of breast cancer (CoMPaS).乳腺癌原发肿瘤和继发远处转移的综合数学生长模型(CoMPaS)。
PLoS One. 2018 Jul 6;13(7):e0200148. doi: 10.1371/journal.pone.0200148. eCollection 2018.
5
Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.二甲双胍在体外和体内均抑制食管鳞状细胞癌的增殖,并增强顺铂的抗癌效果。
PLoS One. 2017 Apr 13;12(4):e0174276. doi: 10.1371/journal.pone.0174276. eCollection 2017.
6
Modeling drug resistance in a conjoint normal-tumor setting.在联合正常组织-肿瘤环境中模拟耐药性。
Theor Biol Med Model. 2015 Jan 15;12:3. doi: 10.1186/1742-4682-12-3.
7
Simplifying the complexity of resistance heterogeneity in metastasis.简化转移过程中耐药异质性的复杂性。
Trends Mol Med. 2014 Mar;20(3):129-36. doi: 10.1016/j.molmed.2013.12.005. Epub 2014 Jan 31.
8
The dynamics of drug resistance: a mathematical perspective.耐药性的动力学:数学视角。
Drug Resist Updat. 2012 Feb-Apr;15(1-2):90-7. doi: 10.1016/j.drup.2012.01.003. Epub 2012 Mar 3.
9
Bayesian enrichment strategies for randomized discontinuation trials.随机停药试验的贝叶斯富集策略
Biometrics. 2012 Mar;68(1):203-11. doi: 10.1111/j.1541-0420.2011.01623.x. Epub 2011 Jun 29.
10
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis.BRCA1 改变在乳腺癌发生中的进化动力学。
J Theor Biol. 2011 Mar 21;273(1):207-15. doi: 10.1016/j.jtbi.2010.12.033. Epub 2010 Dec 29.

本文引用的文献

1
Mutations of Bacteria from Virus Sensitivity to Virus Resistance.细菌从对病毒敏感到对病毒抗性的突变。
Genetics. 1943 Nov;28(6):491-511. doi: 10.1093/genetics/28.6.491.
2
Origin of the resistance of leukaemic cells to folic acid antagonists.白血病细胞对叶酸拮抗剂耐药性的起源。
Nature. 1952 Apr 12;169(4302):628-9. doi: 10.1038/169628a0.
3
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.潜在抗癌剂的实验评估。十三。关于实验性白血病“可治愈性”的标准及动力学
Cancer Chemother Rep. 1964 Feb;35:1-111.
4
Natural history of untreated breast cancer (1805-1933). Comparison of untreated and treated cases according to histological grade of malignancy.未经治疗的乳腺癌的自然史(1805 - 1933年)。根据恶性组织学分级对未经治疗和经治疗的病例进行比较。
Br Med J. 1962 Jul 28;2(5299):213-21. doi: 10.1136/bmj.2.5299.213.
5
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'.接受或未接受辅助性环磷酰胺、甲氨蝶呤、氟尿嘧啶(CMF)治疗的乳腺癌患者复发风险的比较分析。支持“治愈”发生的数据。
Breast Cancer Res Treat. 1999 Feb;53(3):209-15. doi: 10.1023/a:1006134702484.
6
Cancer statistics, 1999.1999年癌症统计数据。
CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1. doi: 10.3322/canjclin.49.1.8.
7
Dormancy of mammary carcinoma after mastectomy.
J Natl Cancer Inst. 1999 Jan 6;91(1):80-5. doi: 10.1093/jnci/91.1.80.
8
Proposal for a new model of breast cancer metastatic development.乳腺癌转移发展新模型的提议。
Ann Oncol. 1997 Nov;8(11):1075-80. doi: 10.1023/a:1008263116022.
9
A mathematical model of drug resistance: heterogeneous tumors.耐药性的数学模型:异质性肿瘤
Math Biosci. 1998 Jan 1;147(1):41-61. doi: 10.1016/s0025-5564(97)00080-1.
10
Computer simulation of a breast cancer metastasis model.
Breast Cancer Res Treat. 1997 Sep;45(2):193-202. doi: 10.1023/a:1005849301420.